Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Glycogen Metabolism Disease Drug Market by Type (OTC, Rx Drugs), By Application (Hospital, Retail Pharmacy) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Glycogen Metabolism Disease Drug Market by Type (OTC, Rx Drugs), By Application (Hospital, Retail Pharmacy) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 326094 4200 Pharma & Healthcare 377 192 Pages 4.8 (35)
                                          

Market Overview:


The global glycogen metabolism disease drug market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of glycogen storage diseases (GSDs), rising awareness about GSDs, and technological advancements in the field of glycogen metabolism disease drugs. However, patent expirations of key drugs and stringent regulatory requirements are restraining the growth of this market. The global glycogen metabolism disease drug market is segmented on the basis of type, application, and region. On the basis of type, it is divided into OTC drugs and Rx drugs. On the basis of application, it is classified into hospital pharmacies and retail pharmacies. Geographically, it is analyzed across North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . Some major players operating in this market are Sanofi Genzyme Corporation (US), Shire plc (Ireland), Akari Therapeutics PLC (UK), Glycagen Inc.


Global Glycogen Metabolism Disease Drug Industry Outlook


Product Definition:


Glycogen metabolism disease is a condition that affects the way the body uses glycogen, a type of sugar. This condition can cause problems with how the body stores and uses energy. Glycogen metabolism disease drug is used to help treat this condition by improving how the body uses glycogen.


OTC:


OTC stands for Over The Counter and is a generic term used to define pharmaceutical products sold in retail stores without a prescription. OTC drugs are intended for household use only and their sale is not restricted by any medical license. Most of the OTC drugs are available as oral tablets, capsules or liquids with some exceptions such as cough syrups which are available in the form of gels or sprays.


Rx Drugs:


Rx drugs are the ones prescribed by doctors to treat a certain disease or condition. The goal of these drugs is to help restore the normal function of a particular body system, which has been affected due to malfunctioning of another body system.


The global Glycogen Metabolism Disease (GMD) drug market size was valued at USD 1.8 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period.


Application Insights:


The retail pharmacy segment held the largest market share of over 70% in 2017. The growing demand for OTC and non-prescription drugs is one of the key factors driving the segment growth. Moreover, increasing awareness about glycogen metabolism disease among a large population that consumes sports drinks and energy bars on a regular basis is expected to propel industry growth during the forecast period.


Hospital was estimated as the second-largest revenue-generating segment owing to high product costs in hospitals that use it as an alternative source for glucose supply during surgeries or emergency situations when blood sugar level drops below normal range.


Regional Analysis:


North America dominated the global glycogen metabolism disease drug market in 2017. The presence of a large number of patients suffering from this condition and increasing awareness levels among people are some factors driving the growth in North America. Moreover, there is an increase in R&D activities for development of new drugs to treat diseases such as diabetes and obesity which are known to cause complications due to glycogen storage disorders, thus leading to an upsurge in demand for treatment options.


Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with growing health awareness among people especially children & adolescents resulting into high unmet medical needs pertainingglycogen metabolic diseases such as hyperosmolarity & dehydration caused by diabetes & hypoglycemia caused by Gaucher's disease amongst others that require immediate attention at hospitals or outpatient clinics thereby fueling market growth.


Growth Factors:


  • Increasing prevalence of glycogen metabolism diseases such as diabetes, obesity, and liver cirrhosis is expected to drive the growth of the glycogen metabolism disease drug market.
  • Rising geriatric population is also a major factor that is anticipated to fuel the demand for glycogen metabolism disease drugs in the near future.
  • Growing awareness about available treatment options for various types of glycogen metabolism diseases is projected to boost the market growth during the forecast period.
  • Technological advancements in drug development are likely to create new opportunities for players operating in this market over the next few years.

Scope Of The Report

Report Attributes

Report Details

Report Title

Glycogen Metabolism Disease Drug Market Research Report

By Type

OTC, Rx Drugs

By Application

Hospital, Retail Pharmacy

By Companies

Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma, Merck

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

192

Number of Tables & Figures

135

Customization Available

Yes, the report can be customized as per your need.


Global Glycogen Metabolism Disease Drug Market Report Segments:

The global Glycogen Metabolism Disease Drug market is segmented on the basis of:

Types

OTC, Rx Drugs

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Retail Pharmacy

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Merck
  2. Novartis
  3. Takeda Pharmaceutical
  4. Astra Zeneca
  5. Boehringer Ingelheim
  6. KOWA
  7. Kythera
  8. Fuji yakuhin
  9. LG Life Science
  10. Metsubishi Tanabe Pharma
  11. Merck

Global Glycogen Metabolism Disease Drug Market Overview


Highlights of The Glycogen Metabolism Disease Drug Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. OTC
    2. Rx Drugs
  1. By Application:

    1. Hospital
    2. Retail Pharmacy
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Glycogen Metabolism Disease Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Glycogen Metabolism Disease Drug Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Glycogen metabolism disease drug is a medication used to treat glycogen storage diseases, such as glycogen storage disease type III (GSD-III). These diseases are caused by a lack of the enzyme that breaks down glycogen into glucose and other molecules. This can lead to too much glycogen in the body, which can cause serious health problems. Glycogen metabolism disease drugs help to restore normal function of this enzyme, which helps to prevent these diseases from developing.

Some of the key players operating in the glycogen metabolism disease drug market are Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma, Merck.

The glycogen metabolism disease drug market is expected to grow at a compound annual growth rate of 7.5%.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glycogen Metabolism Disease Drug Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Glycogen Metabolism Disease Drug Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Glycogen Metabolism Disease Drug Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Glycogen Metabolism Disease Drug Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Glycogen Metabolism Disease Drug Market Size & Forecast, 2020-2028       4.5.1 Glycogen Metabolism Disease Drug Market Size and Y-o-Y Growth       4.5.2 Glycogen Metabolism Disease Drug Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 OTC
      5.2.2 Rx Drugs
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Hospital
      6.2.2 Retail Pharmacy
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Glycogen Metabolism Disease Drug Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Glycogen Metabolism Disease Drug Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 OTC
      9.6.2 Rx Drugs
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Hospital
      9.10.2 Retail Pharmacy
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 OTC
      10.6.2 Rx Drugs
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Hospital
      10.10.2 Retail Pharmacy
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 OTC
      11.6.2 Rx Drugs
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Hospital
      11.10.2 Retail Pharmacy
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 OTC
      12.6.2 Rx Drugs
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Hospital
      12.10.2 Retail Pharmacy
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 OTC
      13.6.2 Rx Drugs
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Hospital
      13.10.2 Retail Pharmacy
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Glycogen Metabolism Disease Drug Market: Competitive Dashboard
   14.2 Global Glycogen Metabolism Disease Drug Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Merck
      14.3.2 Novartis
      14.3.3 Takeda Pharmaceutical
      14.3.4 Astra Zeneca
      14.3.5 Boehringer Ingelheim
      14.3.6 KOWA
      14.3.7 Kythera
      14.3.8 Fuji yakuhin
      14.3.9 LG Life Science
      14.3.10 Metsubishi Tanabe Pharma
      14.3.11 Merck

Our Trusted Clients

Contact Us